{"doi":"10.1158/0008-5472.c.6497288","title":"Data from <i>Pten</i> Haploinsufficiency Accelerates Formation of High-Grade Astrocytomas","abstract":"<div>Abstract<p>We previously reported that central nervous system (CNS) inactivation of <i>Nf1</i> and <i>p53</i> tumor suppressor genes in mice results in the development of low-grade to high-grade progressive astrocytomas. When the tumors achieve high grade, they are frequently accompanied by Akt activation, reminiscent of the frequent association of <i>PTEN</i> mutations in human high-grade glioma. In the present study, we introduced CNS heterozygosity of <i>Pten</i> into the <i>Nf1/p53</i> astrocytoma model. Resulting mice had accelerated morbidity, shortened survival, and full penetrance of high-grade astrocytomas. Haploinsufficiency of <i>Pten</i> accelerated formation of grade 3 astrocytomas, whereas loss of <i>Pten</i> heterozygosity and Akt activation coincided with progression into grade 4 tumors. These data suggest that successive loss of each <i>Pten</i> allele may contribute to <i>de novo</i> formation of high-grade astrocytoma and progression into glioblastoma, respectively, thus providing insight into the etiology of primary glioblastoma. The presence of ectopically migrating neural stem/progenitor lineage cells in presymptomatic <i>Pten</i>-deficient mutant brains supports the notion that these tumors may arise from stem/progenitor cells. [Cancer Res 2008;68(9):3286–94]</p></div>","journal":null,"year":2023,"id":404706,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":0,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.9394,"is_data_producer":false,"deposit_databanks":null,"is_oa":true,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2023-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":285267,"name":"Dawen Zhao","orcid":"0000-0001-6428-1698","position":1,"is_corresponding":false},{"id":1182537,"name":"Jian Chen","orcid":"0000-0002-0438-7631","position":2,"is_corresponding":false},{"id":1183077,"name":"Sheila Alcantara","orcid":null,"position":3,"is_corresponding":false},{"id":1026603,"name":"Yanjiao Li","orcid":"0000-0002-5359-3212","position":4,"is_corresponding":false},{"id":354956,"name":"Dennis K. Burns","orcid":null,"position":5,"is_corresponding":false},{"id":311986,"name":"Ralph P. Mason","orcid":"0000-0001-7517-3721","position":6,"is_corresponding":false},{"id":541605,"name":"Eva Y.-H. P. Lee","orcid":null,"position":7,"is_corresponding":false},{"id":1071982,"name":"Hong Wu","orcid":"0000-0002-1912-1609","position":8,"is_corresponding":false},{"id":667717,"name":"Luis F. Parada","orcid":"0000-0003-2295-1432","position":9,"is_corresponding":false},{"id":578073,"name":"Chang-Hyuk Kwon","orcid":null,"position":0,"is_corresponding":true}],"reference_count":41,"raw_metadata":{"citation_network_status":"fetched"},"created_at":"2026-07-19T01:20:44.591715Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}